Moderna, Inc. (NASDAQ:MRNA) is one of the best healthcare stocks under $50 to invest in. Morgan Stanley reiterated a Hold ...

When U.S. Health Secretary Robert F. Kennedy Jr. announced on Aug. 5 that nearly $500 million to research mRNA vaccines would be canceled, it was one in a continuing line of moves that have put his ...

Health and Human Services Secretary Robert F. Kennedy Jr. revealed his agency will be cutting funding to mRNA development, calling the vaccine technology "ineffective" and claiming it poses more risks ...

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

This week, vaccine manufacturer Moderna revealed that Vinaya Prasad, the top vaccine regulator at the Food and Drug Administration (FDA)—which is a part of HHS— declined to even consider the safety ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

Moderna stock is rated Sell amid FDA setbacks for mRNA-1010, commoditized COVID/RSV sales, and cash burn. Read the analysis ...

BLOOM (TAMPA)- Dr. Kawsar Talaat, Associate Professor of Global Disease Epidemiology and Control at John’s Hopkins University, joins Casey Phillips, guest host of Bloom, guest host for Bloom, to ...

Many public health experts and scientists say they are stunned by Health Secretary Robert F. Kennedy Jr’s decision to cancel nearly half a billion dollars in federal funding for future vaccine ...

Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...

Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight ...